Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
What they are
Mitragynine pseudoindoxyl
A rearrangement product of mitragynine. It appeared in finished products marketed as a 7-OH alternative, often alongside or in place of 7-OH in tablets and shots.
MGM-15, also sold as Oxonol
A semi-synthetic compound related to mitragynine chemistry. It was marketed under brand names as a next-generation option, and MGM-16 appears alongside it in several regulatory actions.
Both were widely recommended. Articles that still rank today for "7-OH alternatives" name them as the answer — those pieces were written before July 2026 and have not been revised.
What happened
In July 2026, DEA filed notices of intent to temporarily schedule 7-OH, mitragynine pseudoindoxyl, MGM-15, and MGM-16. Several states had already moved on some of them through emergency rulemaking.
Brands that had reformulated away from 7-OH into pseudo or MGM had, in many cases, spent months and real money moving from one compound under regulatory pressure to another compound under regulatory pressure. Current status of each.
Why it was predictable
This is the part worth sitting with, because it generalises.
7-OH, pseudoindoxyl, MGM-15, and MGM-16 all share one property: they are built on mitragynine chemistry. Once a chemical family draws regulatory attention, derivatives of that family inherit it. That is not bad luck — it is how the system is designed to work, and it is why the salts-and-isomers principle exists in the first place.
Each successive replacement in this category has bought less time than the one before it, because each was drawn from the same well that regulators were already looking at.
The question to ask of any replacement
Does its parent chemistry have a scheduling history? If yes, you are building on a foundation that has already attracted attention, and the timeline is not in your control. If no, the compound has to be evaluated on its own terms — a much slower process with a much less predictable outcome. That question is worth more than any supplier's assurance.
What this means for choosing next
We are obviously not a neutral party here — we sell 13-OH. So rather than ask you to take our word, here is the test applied honestly to our own product.
13-OH is derived from Corydalis yanhusuo, a poppy-family plant with centuries of documented traditional use and no scheduling history at any level of United States government. Its parent alkaloid, tetrahydropalmatine, is not scheduled. It is an isoquinoline alkaloid — a structurally separate family from the indole alkaloids of the kratom leaf. There is no listed parent for a derivative rule to attach to.
That is a different starting position from the compounds above. It is not a guarantee: no one can promise what any agency will do, and a supplier who does is telling you something about their honesty rather than about the compound. The full reasoning, with the primary sources, is here.
The other honest caveat: 13-OH does not behave like 7-OH. It is a synergist that improves a blend, not a primary active that reproduces another compound's profile. Brands hoping for a drop-in replacement will be disappointed, and we would rather say so now than after you have bought a kilogram. The comparison.
If you are holding affected inventory
We are not able to advise you on this and would be wrong to try. What we would suggest:
- Talk to counsel immediately, before moving product, not after.
- Check your states individually. Several moved before the federal notices, so your position may differ by market.
- Do not assume a notice of intent means nothing has happened yet. Distributors and retailers react to notices, and your commercial position can change well before a scheduling order takes effect.
- Plan the replacement in parallel, not sequentially. The brands that suffered least in this cycle were the ones already benching an alternative when the news landed.
Common questions
Oxonol was a brand name under which MGM-15 was sold. Both names appear in the July 2026 DEA notices context.
That is a question for your counsel and depends on your markets and on where the federal process currently stands. Notices of intent precede scheduling orders, and several states acted earlier. Do not rely on a supplier’s website for this. Current status.
Because they were published before July 2026 and have not been updated. This is a genuine hazard in a fast-moving category — a well-ranked article can be badly out of date and there is nothing on the page to tell you. Check the date on anything you read about this category, including ours.
No, and anyone telling you otherwise is not being straight with you. What we can show you is why its structural position differs from the compounds that have been scheduled, and we maintain a tracker so you hear about changes promptly. The reasoning.